Crenessity Solution
Product Images NDC 70370-5250

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Crenessity (NDC 70370-5250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neurocrine Biosciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Its Molecular Formula Is C27h28clfn2os, And Its Molecular Weight Is 483.04 G/mol With The Following Structure (Crenessity 01)

FDA Label Image

Figure A (Crenessity 02)

This text seems to describe a product related to oral administration, possibly a press-in oral solution syringe bottle with an adapter. It also mentions a syringe with plunger for application.*

FDA Label Image

Figure B (Crenessity 03)

FDA Label Image

Figure C (Crenessity 04)

FDA Label Image

Figure D (Crenessity 05)

FDA Label Image

Figure E (Crenessity 06)

FDA Label Image

Figure F (Crenessity 07)

FDA Label Image

Figure G (Crenessity 08)

FDA Label Image

Figure H (Crenessity 09)

FDA Label Image

Figure I (Crenessity 0a)

FDA Label Image

Figure J (Crenessity 0b)

FDA Label Image

Principal Display Panelndc 70370-5025-1crenessity(crinecerfont) Capsules25 mg60 Capsulesrx Only (Crenessity 0c)

This text appears to be a product description for a medication called Crenessity. Each capsule contains 25 mg of crincerfont. The recommended dosage is not available in the text. The product is child-resistant, with instructions to keep it out of reach of children. The manufacturer is identified as NEURINE®. Additional details such as prescribing information and the company's contact information are not provided in this excerpt.*

FDA Label Image

Principal Display Panelndc 70370-5050-1crenessity(crinecerfont) Capsules50 mg60 Capsulesrx Only (Crenessity 0d)

FDA Label Image

Principal Display Panelndc 70370-5100-1crenessity(crinecerfont) Capsules100 mg30 Capsulesrx Only (Crenessity 0e)

This text provides information about a product called "Aconly capsules" containing 100 mg of "crinecerfont" also known as Crenessity™. The package is child-resistant and has a recommended dosage to be found in the Prescribing Information. It is produced by Neurocrine Biosciences in San Diego, CA. The GTIN number is 0037037051001 with an expiration date indicated as "EXP YYYY MMM 00".*

FDA Label Image

Principal Display Panelndc 70370-5250-1crenessity(crinecerfont) Oral Solution50 mg/ml30 mLrx Only (Crenessity 0f)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.